Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer
Swedish lung cancer radiation study group: the prognostic value of anaemia, thrombocytosis and leukocytosis at time of diagnosis in patients with non-small cell lung cancer
复制标题
DOI：
10.1007/s12032-012-0247-3
复制
发表时间：
2012-12-01
期刊：
影响因子：
3.4
通讯作者：
Bergqvist, Michael
中科院分区：
文献类型：
--
作者：
Holgersson, Georg;Sandelin, Martin;Bergqvist, Michael
非小细胞肺癌（NSCLC）的预后和预测指标有待提高。目前，主要集中在遗传预测标记，而与造血相关的标准血液变量的预后价值受到相对有限的关注。为了研究非小细胞肺癌患者诊断时血红蛋白（Hgb）、血小板（Plt）和白色血细胞（WBC）水平的预后潜力，本研究纳入了835例接受根治性放疗（> 50戈伊）的I-IV期非小细胞肺癌患者。研究WBC、Plt、Hgb、性别、诊断时年龄、分期、手术和一线化疗与总生存率的关系。对于Hgb < 110 g/L和Hgb <110 g/L的患者，中位生存期分别为11.2和14.5个月（p = 0.0032）。对于WBC > 9.0 x 10（9）/L和< 9.0 x 10（9）/L，中位生存期分别为11.6和15.4个月（p < 0.0001）。对于Plt > 350 x 10（9）/L和< 350 x 10（9）/L，中位生存期分别为11.2和14.9个月（p < 0.0001）。所有三种标志物均为病理结果的患者的中位生存期是所有三种标志物均为正常水平的患者的一半（分别为8.0和16.0个月（p < 0.0001））。研究的三种血液学生物标志物的水平与NSCLC的结局显著对应。这些结果表明，标准的血液学变量可用于指导临床医生在决策有关的治疗强度和患者的信息。
There is a need to improve the prognostic and predictive indicators in non-small cell lung cancer (NSCLC). At present, the main focus is on genetic predictive markers while the prognostic value of the standard blood variables related to haematopoiesis has been subjected to relatively limited attention. To study the prognostic potential of haemoglobin (Hgb), platelet (Plt) and white blood cell (WBC) levels at time of diagnosis in NSCLC patients, 835 NSCLC patients, stage I-IV, who received radiotherapy with curative intention (> 50 Gy), were included in the study. WBC, Plt, Hgb, gender, age at diagnosis, stage, surgery and first-line chemotherapy were studied in relation to overall survival. For patients with Hgb < 110 g/L and Hgb a parts per thousand yen 110 g/L), the median survival was 11.2 and 14.5 months, respectively (p = 0.0032). For WBC > 9.0 x 10(9)/L and < 9.0 x 10(9)/L, the median survival was 11.6 and 15.4 months, respectively (p < 0.0001). For Plt > 350 x 10(9)/L and < 350 x 10(9)/L, the median survival was 11.2 and 14.9 months, respectively (p < 0.0001). The median survival in patients with pathological results in all three markers was half of that in patients with normal levels of all three markers (8.0 and 16.0 months, respectively (p < 0.0001). The level of the three studied haematological biomarkers corresponds significantly to outcome in NSCLC. These results indicate that standard haematological variables may be used as guidance for the clinician in the decision-making regarding treatment intensity and patient information.